



A LOCAL TREATMENT PROVEN TO REDUCE HEALING TIME¹



UργοStart[®]
Contact

An innovative non-adhesive, non-occlusive matrix with TLC-NOSF technology. It combines a polyester mesh with the TLC-NOSF formula.

A LOCAL TREATMENT PROVEN TO REDUCE HEALING TIME¹

The UrgoStart® treatment range of dressings is innovative technology combining Technology Lipido-Colloid (TLC) with Nano-Oligo Saccharide Factor (NOSF). Dressings in this range offer an optimum healing process.* The TLC-NOSF combination leads to the restoration of wound bed conditions that promote granulation of chronic wounds, in which a metabolic imbalance has led to a continuous degradation of the extra-cellular matrix, and possibly to delayed healing.

*The recommended treatment duration for UrgoStart® dressings 4-5 weeks or to healing.



UrgoStart® CONTACT



FEATURES

- Proven efficacy
- Incorporates NOSF technology
- Incorporates TLC technology
- Flexible & conformable
- Non-woven substrate
- Seven day wear time

BENEFITS

- Clinical Best Practice
- Inhibits proliferation of MMPs
- Promotes angiogenesis
- Creates a moist wound environment
- Non-adherent
- Atraumatic removal
- Assists in good fit on all wound shapes
- Suitable for deep and cavity wounds
- Can be cut
- Will not shed into the wound
- Reduces need to change contact layer at time of secondary dressing change

INDICATIONS

- Non to low exuding (a secondary absorbent dressing can be used for highly exuding wounds)
 - o Chronic Wounds
 - o Diabetic Foot Ulcers
 - o Leg Ulcers
 - o Pressure Injuries
- Long Standing Acute Wounds
- Wounds where surrounding skin is friable

CONTRAINDICATIONS

- In order not to delay any optimal treatment UrgoStart® Contact is contra-indicated in cancerous wounds and fistula wounds which may reveal a deep abscess
- Not suitable for use during hyperbaric treatment
- Do not use if there is a known sensitivity to UrgoStart® Contact or its components

PRECAUTIONS

- If there are clinical signs of local infection, suitable treatment based on clinical judgement and local protocols is recommended prior to the use of UrgoStart®
- In the case of an atypical ulcer presenting induration or over-granulation, UrgoStart® Contact should only be used after checking for the absence of wound-related malignancy in order not to delay the diagnosis
- In case of deep wounds or cavity wounds, a section of the

UrgoStart® Contact dressing should be left visible to enable easy removal

- The product's action on retriggering the healing process may possibly cause stinging or painful sensations on commencement of treatment. This rarely warrants suspension of treatment
- Do not re-sterilise the dressing. Single use sterile individual packaging: re-using a single use dressing may lead to risks of infection

ORDERING DETAILS

CODE	PRODUCT	DESCRIPTION	DRESSING SIZE	DRESSINGS PER BOX
100379	UrgoStart® Contact	Protease Inhibiting Matrix Contact layer	5x7cm	10
100380	UrgoStart® Contact	Protease Inhibiting Matrix Contact layer	10x10cm	10
100381	UrgoStart® Contact	Protease Inhibiting Matrix Contact layer	15x20cm	10



Non to low exuding wounds (a secondary absorbent dressing can be used for highly exuding wounds)



Cavity or flat wounds



Can be cut



Can be used under compression

1. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153.